Psoriasis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:07:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Psoriasis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis https://clinicaltrials.eu/trial/dose-ranging-study-of-orka-001-in-patients-with-moderate-to-severe-plaque-psoriasis/ Tue, 12 May 2026 06:45:36 +0000 https://clinicaltrials.eu/trial/dose-ranging-study-of-orka-001-in-patients-with-moderate-to-severe-plaque-psoriasis/ This study is being done in people with moderate-to-severe plaque psoriasis, a long-term skin condition that causes raised, red, scaly patches on the skin. The treatment being tested is ORKA-001, given as a subcutaneous injection under the skin. A placebo is also used in the study. The purpose of the study is to find the best dose of ORKA-001 and to compare it with placebo.

People in the study are assigned by chance to receive either ORKA-001 or placebo. The study is double-blinded, which means that the people taking part and the study staff do not know which treatment is given. Treatment is given over time, and the skin condition is checked during the study to see how well the symptoms improve and how long any improvement lasts.

The study also looks at safety, including possible side effects and changes in health checks such as blood tests and heart tracing. The full study lasts up to about 100 weeks.

]]> Study on the Effectiveness and Safety of ESK-001 and Apremilast for Adults with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-esk-001-and-apremilast-for-adults-with-moderate-to-severe-plaque-psoriasis/ Mon, 04 May 2026 08:00:27 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-esk-001-and-apremilast-for-adults-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effectiveness and safety of a new treatment called ESK-001 for patients with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. The study will compare the effects of ESK-001 with a placebo and an existing medication called Otezla, which contains the active ingredient apremilast. ESK-001 is taken as a tablet by mouth, and the study aims to see if it works better than the placebo after 16 weeks of treatment.

Participants in the study will be randomly assigned to receive either ESK-001, Otezla, or a placebo. The treatment period will last up to 24 weeks, during which participants will take the medication orally. The study will monitor the participants’ skin condition and overall health to assess the effectiveness and safety of the treatments. The goal is to determine if ESK-001 can significantly improve the symptoms of plaque psoriasis compared to the placebo and to evaluate its performance against Otezla.

The study is designed to provide valuable information about the potential benefits of ESK-001 for treating moderate to severe plaque psoriasis. By comparing it with a placebo and an existing treatment, researchers hope to understand how well ESK-001 works and its safety profile. This information could help in developing new treatment options for people living with this skin condition.

]]> Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-jnj-77242113-and-deucravacitinib-for-adults-with-moderate-to-severe-plaque-psoriasis/ Mon, 04 May 2026 07:55:30 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-jnj-77242113-and-deucravacitinib-for-adults-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the treatment of moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches on the skin. The study will evaluate a new medication called JNJ-77242113, which is taken as a film-coated tablet. The purpose of the study is to assess how effective and safe this medication is compared to a placebo and another medication called Deucravacitinib, which is already used to treat psoriasis.

Participants in the study will be randomly assigned to receive either the new medication, the placebo, or Deucravacitinib. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment. This helps ensure that the results are unbiased. The study will take place over several weeks, during which participants will take the medication orally and attend regular check-ups to monitor their progress and any side effects.

The goal is to determine if JNJ-77242113 can improve the symptoms of plaque psoriasis more effectively than the placebo or Deucravacitinib. Participants will be monitored for changes in their skin condition and overall health. The study aims to provide valuable information that could lead to new treatment options for people living with moderate to severe plaque psoriasis.

]]> A study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-zasocitinib-in-children-and-adolescents-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:09:47 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-zasocitinib-in-children-and-adolescents-with-moderate-to-severe-plaque-psoriasis/ This study is being conducted to evaluate the effectiveness and safety of zasocitinib in children and adolescents with Plaque Psoriasis, a chronic skin condition characterized by red, itchy, and scaly patches. Participants will receive either zasocitinib, which is an oral medication taken as a film-coated tablet, or a placebo. The study is divided into different groups to look at how the drug works in older children and how the body processes the medicine, known as pharmacokinetics, in younger children.

In the first part of the study, participants are assigned to receive either the active medication or a placebo for 16 weeks. The research aims to see how much the skin improves and if the medication is well-tolerated. Researchers will also look at changes in skin coverage and how much the itching affects daily life. After the initial period, some participants may move into an open-label phase, where everyone receives the active medication.

]]> A study to examine how the body processes and removes DC-806 in healthy male volunteers https://clinicaltrials.eu/trial/a-study-to-examine-how-the-body-processes-and-removes-dc-806-in-healthy-male-volunteers/ Wed, 29 Apr 2026 15:08:54 +0000 https://clinicaltrials.eu/trial/a-study-to-examine-how-the-body-processes-and-removes-dc-806-in-healthy-male-volunteers/ This study aims to investigate how the body processes and eliminates a new substance. The research focuses on a drug known as DC-806 and its labeled version, [14C] DC-806, which contains a traceable marker to help track its movement. This investigation involves healthy individuals to understand the pharmacokinetics, which is the study of how a substance moves through the body, and the metabolism, which is the process by which the body breaks down substances.

Participants will be given a single dose of the medication in the form of an oral film-coated tablet or a capsule. During the study, researchers will monitor the excretion, or the process of eliminating substances from the body, by collecting urine and feces. The study also tracks the presence of the substance in the blood and plasma, which is the liquid part of the blood, to determine how the drug is absorbed and distributed over time.

]]> Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis https://clinicaltrials.eu/trial/long-term-safety-study-of-deucravacitinib-compared-to-ustekinumab-in-adults-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:08:28 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-deucravacitinib-compared-to-ustekinumab-in-adults-with-moderate-to-severe-plaque-psoriasis/ This study involves people with moderate to severe plaque psoriasis, which is a skin condition that causes red, scaly patches on the skin. The treatments being compared in this study are deucravacitinib, which is taken as a tablet by mouth, and ustekinumab, which is given as an injection under the skin. The purpose of this study is to assess the cardiovascular safety of long-term use of deucravacitinib in comparison to ustekinumab in adults with moderate to severe plaque psoriasis. Cardiovascular safety refers to how these medications may affect the heart and blood vessels over time.

People taking part in this study will be adults aged 40 years or older who have moderate to severe plaque psoriasis and who have at least one risk factor that may affect heart health, such as smoking, high blood pressure, high cholesterol, diabetes, obesity, or a family history of heart disease. During the study, participants will receive either deucravacitinib or ustekinumab for up to 60 months. The study will monitor for various heart and blood vessel problems, including heart attacks, strokes, procedures to open blocked blood vessels in the heart, blood clots in the legs or lungs, and heart failure requiring hospital care.

Throughout the study, participants will have regular check-ups that include blood tests to check liver function and cholesterol levels. The study will also track other safety concerns such as serious side effects, infections, and skin cancers. Information will be collected about any side effects that lead to stopping the medication and about deaths from any cause. This study is designed to run for several years to understand the long-term safety of these treatments in people with psoriasis who have risk factors for heart disease.

]]> Testing IDOR-1117-2520 for Adults with Moderate to Severe Chronic Plaque Psoriasis With or Without Psoriatic Arthritis https://clinicaltrials.eu/trial/testing-idor-1117-2520-for-adults-with-moderate-to-severe-chronic-plaque-psoriasis-with-or-without-psoriatic-arthritis/ Wed, 29 Apr 2026 15:08:10 +0000 https://clinicaltrials.eu/trial/testing-idor-1117-2520-for-adults-with-moderate-to-severe-chronic-plaque-psoriasis-with-or-without-psoriatic-arthritis/ This study involves people with moderate to severe chronic plaque psoriasis, a condition where the skin develops raised, red, scaly patches that can be itchy and painful. Some people in this study may also have psoriatic arthritis, which is joint inflammation that can occur along with psoriasis. The study will test a medication called IDOR-1117-2520, which is given as a gastro-resistant tablet (a type of tablet that does not break down in the stomach but passes through to the intestines). Some participants will receive the actual medication while others will receive a matching placebo.

The purpose of this study is to explore how well IDOR-1117-2520 works compared to placebo in improving the skin condition of people with moderate to severe chronic plaque psoriasis, and to check if the medication is safe. The study will look at changes in a measurement called the Psoriasis Area and Severity Index, which is a way doctors score how much of the body is affected by psoriasis and how severe the patches are. The study will also examine whether the overall appearance of the skin improves as assessed by doctors, and will monitor for any unwanted effects or side effects that may occur during treatment.

The study will last for twelve weeks of treatment, during which participants will take the medication or placebo by mouth. Throughout the study, participants will have regular check-ups where doctors will examine their skin, measure vital signs like blood pressure and heart rate, check body weight, take blood samples for laboratory tests, and perform electrocardiogram tests (a test that records the electrical activity of the heart). Participants who are able to become pregnant will need to have pregnancy tests and use reliable birth control methods during the study and for thirty days after stopping the medication.

]]> Comparison of zasocitinib and deucravacitinib in adults with moderate to severe plaque psoriasis https://clinicaltrials.eu/trial/comparison-of-zasocitinib-and-deucravacitinib-in-adults-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:07:23 +0000 https://clinicaltrials.eu/trial/comparison-of-zasocitinib-and-deucravacitinib-in-adults-with-moderate-to-severe-plaque-psoriasis/ This clinical trial focuses on comparing two medications in people with moderate-to-severe plaque psoriasis, a chronic skin condition that causes red, scaly patches on the skin that have been present for at least 6 months. The study will evaluate two oral medications: zasocitinib (also known as TAK-279) and deucravacitinib (SOTYKTU), which are taken once daily. Some participants will receive placebo instead of active medication.

The purpose of this research is to determine if zasocitinib works better than deucravacitinib in treating moderate-to-severe plaque psoriasis. The study will specifically look at how well these medications clear the skin condition by measuring improvements in the affected areas of skin and the severity of psoriasis symptoms.

During the 16-week study period, participants will take their assigned medication by mouth once each day. The effectiveness of the treatment will be evaluated by examining changes in the skin’s appearance and measuring the reduction in psoriasis symptoms. Throughout the study, doctors will monitor participants’ health and safety through regular check-ups, including physical examinations and laboratory tests.

]]> Study of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis https://clinicaltrials.eu/trial/study-of-deucravacitinib-compared-to-placebo-in-adolescents-aged-12-17-years-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:07:18 +0000 https://clinicaltrials.eu/trial/study-of-deucravacitinib-compared-to-placebo-in-adolescents-aged-12-17-years-with-moderate-to-severe-plaque-psoriasis/ This study focuses on evaluating a medication called deucravacitinib (also known as BMS-986165) for treating moderate to severe plaque psoriasis in young people between 12 and 18 years old. Plaque psoriasis is a skin condition that causes red, thick, scaly patches on the skin. The purpose of this research is to determine how well the medication works and how safe it is for adolescent patients.

The study will test deucravacitinib against placebo in participants who have had plaque psoriasis for at least 6 months and who could benefit from whole-body treatment. The medication comes in the form of film-coated tablets that are taken by mouth. During the study, researchers will monitor how the skin condition improves and track any changes in participants’ health.

The main focus will be on measuring improvements in the skin condition after 16 weeks of treatment. The study will also look at how the medication affects participants’ growth and development. Throughout the study, doctors will regularly check participants’ overall health, including their height, weight, and physical development.

]]> Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis https://clinicaltrials.eu/trial/study-of-zasocitinib-tak-279-and-apremilast-compared-to-placebo-in-adults-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:07:17 +0000 https://clinicaltrials.eu/trial/study-of-zasocitinib-tak-279-and-apremilast-compared-to-placebo-in-adults-with-moderate-to-severe-plaque-psoriasis/ This clinical study focuses on treating moderate-to-severe plaque psoriasis, a chronic skin condition that causes raised, red, scaly patches on the skin. The study will evaluate a new medication called TAK-279 (zasocitinib) compared to apremilast (Otezla) and placebo. The main purpose is to determine how well TAK-279 works when taken as a daily oral tablet for 16 weeks in people with this type of psoriasis.

The study involves taking either TAK-279, apremilast, or placebo in the form of tablets that are swallowed. During the study, doctors will monitor how well the medications work by examining changes in the skin’s appearance and the extent of psoriasis coverage on the body. They will look at improvements in skin clearance and reduction in psoriasis symptoms.

The research will include periods where some participants may switch between different treatments to better understand how the medication works over time. The study will track various aspects of psoriasis, including how it affects the scalp, nails, hands, and feet. Participants will be monitored for approximately 60 weeks to evaluate both the effectiveness and safety of the treatment.

]]> Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis https://clinicaltrials.eu/trial/study-of-tak-279-and-apremilast-for-adults-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:07:16 +0000 https://clinicaltrials.eu/trial/study-of-tak-279-and-apremilast-for-adults-with-moderate-to-severe-plaque-psoriasis/ This study focuses on patients with moderate-to-severe plaque psoriasis, a chronic skin condition causing red, scaly patches on the skin that has been present for at least 6 months. The study will evaluate a new medication called TAK-279 (zasocitinib) compared to Otezla (apremilast) and placebo. All medications will be given as tablets that are taken by mouth once daily.

The main purpose is to determine how well TAK-279 works in treating plaque psoriasis over a 16-week period. The study will measure improvements in skin appearance and the extent of psoriasis coverage on the body. The total duration of treatment will be 52 weeks.

During the study, participants will be randomly assigned to receive either TAK-279, Otezla, or placebo tablets. The effectiveness of the treatment will be assessed by examining changes in the appearance and severity of psoriasis symptoms, including improvements in skin clearance and reduction in the affected areas. The study will also evaluate how the medications affect psoriasis on specific body areas such as the scalp, nails, hands, and feet.

]]> Study of early versus late risankizumab treatment to evaluate immune cell response in patients with moderate to severe psoriasis https://clinicaltrials.eu/trial/study-of-early-versus-late-risankizumab-treatment-to-evaluate-immune-cell-response-in-patients-with-moderate-to-severe-psoriasis/ Wed, 29 Apr 2026 15:06:54 +0000 https://clinicaltrials.eu/trial/study-of-early-versus-late-risankizumab-treatment-to-evaluate-immune-cell-response-in-patients-with-moderate-to-severe-psoriasis/ This study focuses on patients with moderate-to-severe psoriasis, a skin condition that causes red, scaly patches on the skin. The research examines the effects of risankizumab, a medication given as an injection under the skin, in treating this condition. The study specifically looks at how the timing of treatment affects the results – comparing patients who start treatment early (within one year of first symptoms) versus those who have had psoriasis for more than ten years.

The medication being studied, Skyrizi (risankizumab), is administered as a solution for injection. Participants receive injections containing 150 mg of the medication. The study aims to determine if early treatment with risankizumab is more effective at targeting specific immune cells in the skin compared to treatment started later in the disease course.

The study lasts for approximately one year, during which participants receive regular injections and undergo skin evaluations. The treatment schedule follows standard dosing guidelines, with participants receiving injections at specific intervals throughout the study period. The total amount of medication received during the study does not exceed 700 mg.

]]> Study to measure bimekizumab concentration in breast milk of breastfeeding mothers with psoriasis, psoriatic arthritis, axial spondyloarthritis, or hidradenitis suppurativa https://clinicaltrials.eu/trial/study-to-measure-bimekizumab-concentration-in-breast-milk-of-breastfeeding-mothers-with-psoriasis-psoriatic-arthritis-axial-spondyloarthritis-or-hidradenitis-suppurativa/ Wed, 29 Apr 2026 15:06:37 +0000 https://clinicaltrials.eu/trial/study-to-measure-bimekizumab-concentration-in-breast-milk-of-breastfeeding-mothers-with-psoriasis-psoriatic-arthritis-axial-spondyloarthritis-or-hidradenitis-suppurativa/ This study will investigate how much bimekizumab passes into breast milk in mothers who are being treated with this medication. The study includes women with several chronic inflammatory conditions including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and plaque psoriasis. Bimekizumab is given as an injection under the skin using either pre-filled syringes or pre-filled pens.

The study will collect breast milk samples from mothers who are already receiving bimekizumab treatment as prescribed by their doctor. Samples will be taken over a period of two weeks, with additional samples collected depending on how often the participant receives their medication. The main purpose is to measure the amount of medication that passes into breast milk.

Participants must be at least 18 years old, currently breastfeeding, and have been receiving bimekizumab treatment for at least 12 weeks after giving birth. The study will monitor both mothers and infants for any side effects throughout the study period. The medication dose and schedule will continue as previously prescribed by the participant’s doctor.

]]> Study on the Effects and Safety of Piclidenoson for Patients with Moderate-to-Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-piclidenoson-for-patients-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:05:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-piclidenoson-for-patients-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effects of a medication called Piclidenoson on individuals with plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. The study will compare the effects of Piclidenoson, which is taken as a tablet, to a placebo. The purpose of the study is to evaluate how effective and safe Piclidenoson is for people with moderate-to-severe plaque psoriasis.

Participants in the study will take Piclidenoson orally, which means they will swallow the tablets. The study will last for a period of time, during which participants will be monitored to see how their psoriasis responds to the treatment. The main goal is to see if Piclidenoson can help reduce the severity of the psoriasis symptoms and improve the overall condition of the skin. The study will also look at the safety of using Piclidenoson over the course of the treatment.

Throughout the study, participants will have regular check-ups to assess their progress. The effectiveness of the treatment will be measured by looking at improvements in the skin condition, such as the reduction of red, scaly patches. The study aims to provide valuable information on whether Piclidenoson can be a beneficial treatment option for those suffering from moderate-to-severe plaque psoriasis.

]]> Study on How Bimekizumab Affects People with Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis https://clinicaltrials.eu/trial/study-on-how-bimekizumab-affects-people-with-moderate-to-severe-plaque-psoriasis-and-psoriatic-arthritis/ Wed, 29 Apr 2026 15:05:34 +0000 https://clinicaltrials.eu/trial/study-on-how-bimekizumab-affects-people-with-moderate-to-severe-plaque-psoriasis-and-psoriatic-arthritis/ This clinical trial is focused on studying the effects of a medication called bimekizumab in people with moderate to severe plaque psoriasis and those who also have psoriatic arthritis. Plaque psoriasis is a skin condition that causes red, scaly patches, while psoriatic arthritis is a type of arthritis that affects some people with psoriasis, leading to joint pain and swelling. Bimekizumab is given as a solution for injection using a prefilled pen, which allows for self-administration under the skin.

The purpose of the study is to understand how bimekizumab affects certain biological markers in the body, which are indicators of how the disease is behaving. Participants will receive the treatment over a period of time, and the study will observe changes in these markers at different points, particularly at Week 48. The study will also monitor any side effects that may occur during the treatment period.

Participants will be asked to provide skin samples to help researchers analyze the effects of the medication on gene expression, which is the process by which information from a gene is used to create proteins that affect cell function. This study aims to provide insights into how bimekizumab works in treating these conditions and to gather information on its safety and effectiveness.

]]> Study on the Effectiveness and Safety of Tildrakizumab for Patients with Moderate to Severe Genital Psoriasis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tildrakizumab-for-patients-with-moderate-to-severe-genital-psoriasis/ Wed, 29 Apr 2026 15:04:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-tildrakizumab-for-patients-with-moderate-to-severe-genital-psoriasis/ This clinical trial is focused on studying moderate to severe genital psoriasis, a skin condition that causes red, scaly patches in the genital area. The study will evaluate the effectiveness and safety of a medication called tildrakizumab, which is given as an injection under the skin. Participants in the study will receive either tildrakizumab or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to assess how well tildrakizumab works in reducing the symptoms of genital psoriasis over a period of 16 weeks. Participants will be randomly assigned to receive either the medication or the placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The main goal is to see if tildrakizumab can help clear the skin or significantly reduce the severity of the psoriasis compared to the placebo.

Throughout the study, participants will have regular check-ups to monitor their progress and any side effects. The study will last for a total of 52 weeks, allowing researchers to gather comprehensive data on the long-term effects and safety of tildrakizumab. This research aims to provide valuable insights into the treatment of moderate to severe genital psoriasis and potentially improve the quality of life for those affected by this condition.

]]> Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-jnj-77242113-compared-to-placebo-and-ustekinumab-for-patients-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:04:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-jnj-77242113-compared-to-placebo-and-ustekinumab-for-patients-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effectiveness and safety of a new treatment for moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches. The study will compare a new medication, known by its code name JNJ-77242113, with a commonly used treatment called Ustekinumab and a placebo. The purpose of the study is to evaluate how well JNJ-77242113 works in treating this condition.

Participants in the study will receive either the new medication, Ustekinumab, or a placebo. The new medication, JNJ-77242113, is taken as a film-coated tablet, while Ustekinumab is given as an injection. The study will last for several weeks, during which participants will be monitored to see how their psoriasis responds to the treatment. The goal is to see if the new medication can improve the symptoms of psoriasis, such as reducing the size and severity of the skin patches.

The study will involve regular check-ups to assess the condition of the skin and overall health. Participants will be randomly assigned to one of the treatment groups, and neither the participants nor the researchers will know which treatment is being given to ensure unbiased results. The study aims to provide valuable information on whether JNJ-77242113 is a safe and effective option for treating moderate to severe plaque psoriasis.

]]> Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-esk-001-for-patients-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:04:41 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-esk-001-for-patients-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the long-term effects of a medication called ESK-001 in patients with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches on the skin. The study aims to evaluate the safety, effectiveness, and how well the response to the treatment lasts over time.

Participants in the study will receive ESK-001, which is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The treatment period can last up to 48 weeks, and the study will monitor how patients respond to the medication over this time. The goal is to see if ESK-001 can help reduce the symptoms of plaque psoriasis and maintain these improvements.

The study will also look at the quality of life of participants, assessing changes in their daily living and comfort levels. By the end of the study, researchers hope to gather valuable information on the long-term use of ESK-001 for treating moderate to severe plaque psoriasis, which could help in managing the condition more effectively in the future.

]]> Study on the Effectiveness and Safety of ESK-001 and Apremilast for Patients with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-esk-001-and-apremilast-for-patients-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:04:08 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-esk-001-and-apremilast-for-patients-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effectiveness and safety of a new treatment for Moderate to Severe Plaque Psoriasis, a skin condition that causes red, scaly patches on the skin. The study will test a medication called ESK-001, which is taken as a tablet by mouth. The trial will compare the effects of ESK-001 with a placebo and another medication called Otezla, which contains the active ingredient apremilast.

The purpose of the study is to determine if ESK-001 is more effective than a placebo after 16 weeks of treatment. Participants will be randomly assigned to receive either ESK-001, Otezla, or a placebo. The study will last up to 24 weeks, during which participants will take the medication orally. The trial aims to see improvements in the skin condition by measuring changes in the severity and extent of the psoriasis patches.

Throughout the study, participants will be monitored to assess the safety and effectiveness of the treatments. The trial will help researchers understand if ESK-001 can provide better outcomes for people with moderate to severe plaque psoriasis compared to existing treatments. This study is an important step in finding new and effective ways to manage this chronic skin condition.

]]> Study on Sodium Fluoride (18F) PET-CT Scans for Detecting Bone Changes in Psoriasis Patients at Risk of Psoriatic Arthritis https://clinicaltrials.eu/trial/study-on-sodium-fluoride-18f-pet-ct-scans-for-detecting-bone-changes-in-psoriasis-patients-at-risk-of-psoriatic-arthritis/ Wed, 29 Apr 2026 15:03:54 +0000 https://clinicaltrials.eu/trial/study-on-sodium-fluoride-18f-pet-ct-scans-for-detecting-bone-changes-in-psoriasis-patients-at-risk-of-psoriatic-arthritis/ This clinical trial is focused on studying Psoriasis, a skin condition that causes red, itchy, and scaly patches, and its potential progression to Psoriatic Arthritis, a type of arthritis that affects some people with psoriasis. The study will use a special imaging technique called [18F]Fluoride PET-CT to look for new bone formation in the body. This imaging method involves a solution called Sodium Fluoride (18F), which is injected into the body to help highlight areas of interest during the scan.

The purpose of the study is to see if this imaging technique can effectively detect changes in the bones of people with psoriasis who are at risk of developing psoriatic arthritis. Participants will undergo whole-body scans to identify any new bone growth. The study will track the number and location of any positive findings from the scans. Additionally, researchers will observe how these findings relate to the development of psoriatic arthritis over a two-year period.

Throughout the study, participants will receive the Sodium Fluoride (18F) injection and undergo the PET-CT scan. The study aims to provide valuable insights into the early detection of bone changes in psoriasis patients, potentially leading to better management and treatment of those at risk for psoriatic arthritis. A placebo may be used in some cases to compare results. The study is expected to continue until 2027.

]]> Study on the Effects of IDP-118 Lotion (Tazarotene and Halobetasol Propionate) for Children with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effects-of-idp-118-lotion-tazarotene-and-halobetasol-propionate-for-children-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:03:51 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-idp-118-lotion-tazarotene-and-halobetasol-propionate-for-children-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effects of a treatment for plaque psoriasis, a skin condition that causes red, scaly patches. The treatment being tested is a lotion called IDP-118, also known as Duobrii, which contains two active ingredients: tazarotene and halobetasol propionate. These ingredients are applied to the skin in the form of a liquid.

The purpose of the study is to evaluate the safety and absorption of the IDP-118 lotion when used by children and teenagers with moderate to severe plaque psoriasis. The study will also look at how the body processes the medication and whether it affects the body’s hormone system, specifically the hypothalamic-pituitary-adrenal (HPA) axis, which is involved in stress response and hormone production.

Participants in the study will apply the lotion to their skin once a day for up to eight weeks. The study will monitor how the medication is absorbed into the body and its potential effects on the participants’ health. This research aims to provide more information about the treatment’s safety and effectiveness for young people with plaque psoriasis.

]]> Study Comparing CT-P55 and Secukinumab for Moderate to Severe Plaque Psoriasis Patients https://clinicaltrials.eu/trial/study-comparing-ct-p55-and-secukinumab-for-moderate-to-severe-plaque-psoriasis-patients/ Wed, 29 Apr 2026 15:03:44 +0000 https://clinicaltrials.eu/trial/study-comparing-ct-p55-and-secukinumab-for-moderate-to-severe-plaque-psoriasis-patients/ This clinical trial is focused on studying a skin condition called plaque psoriasis, which is characterized by red, scaly patches on the skin. The study will compare two treatments: CT-P55 and Cosentyx. Both treatments contain the active substance secukinumab, which is a type of protein designed to help reduce inflammation and improve the symptoms of psoriasis.

The purpose of the study is to determine if CT-P55 is as effective and safe as Cosentyx for treating moderate to severe plaque psoriasis. Participants in the study will receive either CT-P55 or Cosentyx through injections under the skin. The study will last for several weeks, during which the effects of the treatments will be closely monitored.

Throughout the study, participants will have regular check-ups to assess the changes in their psoriasis symptoms. The main goal is to see how much the psoriasis improves by measuring the change in the Psoriasis Area and Severity Index (PASI) score after eight weeks of treatment. This will help researchers understand if CT-P55 can be a reliable alternative to Cosentyx for people with plaque psoriasis.

]]> Study on the Effectiveness of LY4100511 for Adults with Moderate-to-Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ly4100511-for-adults-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:03:20 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ly4100511-for-adults-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effects of a new treatment for plaque psoriasis, a skin condition that causes red, scaly patches on the skin. The treatment being tested is a medication known by its code name LY4100511 or DC-853. This medication works by inhibiting certain proteins called cytokines, specifically IL-17, which are involved in the inflammation process that contributes to psoriasis. The study will compare different doses of LY4100511 to see how effective they are in treating moderate-to-severe plaque psoriasis.

The purpose of the study is to evaluate the effectiveness of LY4100511 in reducing the symptoms of plaque psoriasis. Participants in the study will be randomly assigned to receive either the active medication or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for up to 12 weeks, during which participants will take the medication in tablet form by mouth. Throughout the study, participants will have regular check-ups to monitor their condition and any changes in their symptoms.

By the end of the study, researchers aim to determine how well LY4100511 works in improving the skin condition of those with moderate-to-severe plaque psoriasis. The study will also gather information on the safety of the medication and any side effects that may occur. This research is important for developing new treatments that can help manage plaque psoriasis more effectively.

]]> Study on the Effects of Deucravacitinib for Patients with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effects-of-deucravacitinib-for-patients-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:03:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-deucravacitinib-for-patients-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effects of a medication called Sotyktu, which contains the active ingredient deucravacitinib, on a skin condition known as plaque psoriasis. Plaque psoriasis is a chronic skin disease that causes red, scaly patches on the skin. The study aims to understand how this medication affects the immune system and the genes involved in causing psoriasis, especially in areas that are difficult to treat, such as the scalp, palms, and soles of the feet.

Participants in the study will take Sotyktu in the form of 6 mg film-coated tablets once a day for a period of 16 weeks. The study will compare the changes in certain genes and immune cells before and after the treatment. This will help researchers learn more about how the medication works in different types of psoriasis plaques, including those that are harder to treat.

The purpose of this study is to assess the changes in the expression of specific genes and the distribution of immune cells in the skin affected by psoriasis. By doing so, the study hopes to provide insights into the effectiveness of Sotyktu in managing moderate to severe plaque psoriasis and improving the quality of life for those affected by this condition. The study is expected to continue until March 2027.

]]> Study on Long-term Safety and Effectiveness of Zasocitinib for Patients with Moderate-to-Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-zasocitinib-for-patients-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:02:47 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effectiveness-of-zasocitinib-for-patients-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the long-term effects of a medication called Zasocitinib (also known by its code name TAK-279) in individuals with moderate-to-severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. The purpose of the study is to evaluate how safe and tolerable the medication is when taken over an extended period.

Participants in the study will take Zasocitinib in the form of a film-coated tablet, which is taken orally once a day. The study will monitor participants over a period of time to observe any side effects or changes in their condition. The study aims to see if the medication can help improve the symptoms of plaque psoriasis, such as reducing the size and severity of the skin patches.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur while taking the medication. They will also look for improvements in the condition, such as a significant reduction in the psoriasis area and severity. The study is designed to provide valuable information about the long-term use of Zasocitinib for treating moderate-to-severe plaque psoriasis.

]]> Study on the Effects of IDP-122 Lotion for Children with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effects-of-idp-122-lotion-for-children-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 15:02:40 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-idp-122-lotion-for-children-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying plaque psoriasis, a skin condition that causes red, scaly patches on the skin. The treatment being tested is a lotion called Bryhali, which contains the active ingredient halobetasol propionate. This lotion is applied directly to the skin and is designed to help reduce the symptoms of plaque psoriasis.

The purpose of the study is to evaluate the safety and effects of the IDP-122 Lotion when used by children and teenagers with moderate to severe plaque psoriasis. Participants will apply the lotion once daily for a period of eight weeks. The study will also look at how the body absorbs the medication and its potential impact on the hypothalamic-pituitary-adrenal (HPA) axis, which is a system in the body that helps regulate stress and other important functions.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to provide valuable information about the use of this lotion in young people with plaque psoriasis, helping to improve treatment options for this condition.

]]> Study on the Effectiveness and Safety of 0.1% Mometasone Furoate Emulsion and Ecural Cream for Adults with Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-0-1-mometasone-furoate-emulsion-and-ecural-cream-for-adults-with-plaque-psoriasis/ Wed, 29 Apr 2026 15:00:47 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-0-1-mometasone-furoate-emulsion-and-ecural-cream-for-adults-with-plaque-psoriasis/ This clinical trial is focused on studying the treatment of plaque psoriasis, a common skin condition that causes red, scaly patches on the skin. The study will evaluate the effectiveness and safety of a treatment called 0.1% mometasone furoate cutaneous emulsion, which is a type of medication applied to the skin. This treatment will be compared to a similar product called Ecural Fettcreme and a placebo, which is a version of the treatment without the active ingredient.

The purpose of the study is to determine if the mometasone furoate cutaneous emulsion is as effective as the Ecural Fettcreme in treating plaque psoriasis and to see if it works better than the placebo. Participants in the study will apply the treatments to their skin over a period of three weeks. The study will involve regular assessments to monitor changes in the skin condition, focusing on improvements in redness, thickness, and scaling of the affected areas.

Throughout the study, participants will be observed to ensure their safety and to track the effectiveness of the treatments. The goal is to find a reliable and safe treatment option for individuals with plaque psoriasis, improving their quality of life by reducing the symptoms associated with this skin condition.

]]> Study on Proactive Drug Monitoring with Secukinumab, Ixekizumab, or Guselkumab for Patients with Moderate-to-Severe Psoriasis https://clinicaltrials.eu/trial/study-on-proactive-drug-monitoring-with-secukinumab-ixekizumab-or-guselkumab-for-patients-with-moderate-to-severe-psoriasis/ Wed, 29 Apr 2026 15:00:07 +0000 https://clinicaltrials.eu/trial/study-on-proactive-drug-monitoring-with-secukinumab-ixekizumab-or-guselkumab-for-patients-with-moderate-to-severe-psoriasis/ This clinical trial is focused on studying the treatment of moderate-to-severe psoriasis, a skin condition that causes red, itchy, and scaly patches. The study will use three different medications: secukinumab, ixekizumab, and guselkumab. These medications are known as biologics, which are treatments made from living organisms or their cells. They are administered as a solution for injection, either in a pre-filled pen or syringe.

The purpose of the study is to compare two approaches to using these biologics: proactive therapeutic drug monitoring (TDM) and routine care. Proactive TDM involves regularly checking the levels of the drug in the body to adjust the dose if necessary, while routine care follows the standard dosing schedule without such monitoring. The study will last for 18 months, during which participants will receive one of the biologics and be monitored for their response to the treatment.

Throughout the study, participants will have regular check-ups every three months to assess their skin condition and overall health. The main goal is to see if proactive TDM is as effective as routine care in maintaining control over psoriasis symptoms. Participants will also be monitored for any side effects or changes in their condition, such as new or worsening joint pain, which can sometimes occur with psoriasis. The study aims to provide valuable information on the best way to use these biologics for treating moderate-to-severe psoriasis.

]]> Study of deucravacitinib in adults with plaque psoriasis: Effects on immune system cells https://clinicaltrials.eu/trial/study-on-the-effects-of-deucravacitinib-on-t-memory-like-cells-in-adults-with-plaque-psoriasis/ Wed, 29 Apr 2026 14:59:47 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-deucravacitinib-on-t-memory-like-cells-in-adults-with-plaque-psoriasis/ This study focuses on patients with plaque psoriasis, a skin condition that causes red, scaly patches on the skin. The research examines how deucravacitinib (also known as Sotyktu) affects certain immune cells in people who have had psoriasis for less than 5 years. The medication comes in the form of film-coated tablets that are taken by mouth.

The purpose of this research is to understand how this medication works by studying specific immune cells called TRM-like cells (tissue-resident memory-like cells) that play a role in psoriasis. The study will look at changes in these cells and related substances in the body over a 24-week treatment period.

During the study, participants will receive Sotyktu tablets containing 6 milligrams of medication to be taken daily. The research will examine how the treatment affects both the number and activity of certain immune cells, as well as monitoring improvements in psoriasis symptoms.

]]> Study on the Safety and Immune Response of Shingrix Vaccine in Patients with Psoriasis or Psoriatic Arthritis https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-shingrix-vaccine-in-patients-with-psoriasis-or-psoriatic-arthritis/ Wed, 29 Apr 2026 14:58:59 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-shingrix-vaccine-in-patients-with-psoriasis-or-psoriatic-arthritis/ This clinical trial is focused on studying the safety and immune response of the vaccine Shingrix in patients who have Psoriasis or Psoriatic Arthritis. Psoriasis is a skin condition that causes red, itchy, and scaly patches, while Psoriatic Arthritis is a type of arthritis that affects some people with Psoriasis. The vaccine being tested, Shingrix, is designed to protect against shingles, a painful rash caused by the reactivation of the chickenpox virus. The vaccine contains a component called recombinant varicella zoster virus glycoprotein E, which helps the body build immunity against the virus.

The purpose of this study is to investigate how safe the Shingrix vaccine is for people with these conditions and how it affects their disease activity. Participants in the study will receive the vaccine and be monitored over a period of time to see if there are any changes in their Psoriasis or Psoriatic Arthritis symptoms. The study will also look at how well the immune system responds to the vaccine by measuring certain immune markers in the blood.

Throughout the study, participants will receive two doses of the Shingrix vaccine, given as an injection into the muscle. They will be observed for any side effects, such as reactions at the injection site or other health changes. The study will last for about a year, with regular check-ups to ensure the safety and effectiveness of the vaccine. Participants will also be checked for any signs of shingles or related complications during the study period.

]]> Study on the Effectiveness and Safety of Vibozilimod for Adults with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-vibozilimod-for-adults-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 14:57:19 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-vibozilimod-for-adults-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effects of a new treatment for moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches on the skin. The treatment being tested is called SCD-044, which is taken in the form of tablets. The active ingredient in these tablets is vibozilimod, a type of medicine known as a selective immunosuppressive agent. This means it works by selectively reducing the activity of the immune system, which can help in managing the symptoms of psoriasis.

The purpose of this study is to determine how effective and safe SCD-044 is in treating moderate to severe plaque psoriasis. Participants in the study will be randomly assigned to receive either the SCD-044 tablets or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for up to 52 weeks, and participants will take the tablets orally. The main goal is to see if there is at least a 75% improvement in the severity and area of psoriasis after 16 weeks of treatment.

Throughout the study, participants will be monitored to assess the effectiveness of the treatment and to ensure their safety. The study aims to provide valuable information on whether SCD-044 can be a beneficial treatment option for those suffering from moderate to severe plaque psoriasis. This research could potentially lead to new ways to manage this challenging skin condition.

]]> Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-deucravacitinib-for-patients-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 14:30:27 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-efficacy-of-deucravacitinib-for-patients-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the long-term safety and effectiveness of a medication called deucravacitinib in individuals with moderate-to-severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. The study involves taking deucravacitinib, which is provided in the form of a film-coated tablet, and aims to understand how safe and tolerable it is for long-term use in treating this condition.

Participants in the study will receive deucravacitinib, and some may receive a placebo to compare the effects. The study is designed to observe any side effects or adverse events that may occur over time. The goal is to gather information on how well the medication works and how safe it is for people with moderate-to-severe plaque psoriasis.

The study will be conducted over a period of time, allowing researchers to collect data on the medication’s impact on the skin condition. Participants will be monitored for any changes in their condition and any potential side effects. This information will help in understanding the long-term benefits and risks of using deucravacitinib for treating plaque psoriasis.

]]> Study on the Safety, Effectiveness, and Blood Movement of Bimekizumab in Adolescents with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-the-safety-effectiveness-and-blood-movement-of-bimekizumab-in-adolescents-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 14:29:57 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-effectiveness-and-blood-movement-of-bimekizumab-in-adolescents-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying moderate to severe plaque psoriasis, a skin condition that causes red, scaly patches on the skin. The study is testing a treatment called bimekizumab, which is given as a solution for injection. Bimekizumab is also known by the code name UCB4940. The purpose of the study is to learn about the safety of bimekizumab, how well it works, and how it moves through the bloodstream in adolescents with this type of psoriasis.

Participants in the study will receive bimekizumab through an injection under the skin. The study will follow participants over a period of time to monitor the levels of the medication in their blood at various points, such as weeks 0, 1, 4, 8, 12, and so on, up to week 124. The study will also look at any side effects that may occur and how the participants’ psoriasis responds to the treatment.

Throughout the study, changes in participants’ health will be observed, including vital signs like blood pressure and heart rate, as well as blood tests to check for any changes in blood cells and chemistry. The study will also assess improvements in the skin condition using specific measures like the Psoriasis Area and Severity Index (PASI) and the Investigator’s Global Assessment (IGA). The goal is to gather comprehensive information on how bimekizumab affects adolescents with moderate to severe plaque psoriasis.

]]> Study on the Effects of JNJ-81241459 for Patients with Moderate to Severe Psoriasis https://clinicaltrials.eu/trial/study-on-the-effects-of-jnj-81241459-for-patients-with-moderate-to-severe-psoriasis/ Wed, 29 Apr 2026 14:29:37 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-jnj-81241459-for-patients-with-moderate-to-severe-psoriasis/ This clinical trial is focused on studying the effects of a potential new medicine called JNJ-81241459 for treating individuals with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin. The study aims to evaluate how effective and safe this new medicine is compared to an inactive medicine, also known as a placebo.

Participants in the study will receive either the new medicine JNJ-81241459 or a placebo in the form of tablets. The study will compare different doses of the new medicine to see which is most effective. The treatment period will last for up to 12 weeks, during which participants will take the tablets orally, meaning by mouth. The goal is to determine if the new medicine can significantly improve the symptoms of plaque psoriasis compared to the placebo.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the new medicine or the placebo. This helps ensure that the results are unbiased. The main objective is to see if participants achieve a significant reduction in their psoriasis symptoms by the end of the study period. This trial is an important step in potentially providing a new treatment option for those affected by moderate to severe plaque psoriasis.

]]> Study on Guselkumab for Patients with Moderate-to-Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-guselkumab-for-patients-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 14:28:47 +0000 https://clinicaltrials.eu/trial/study-on-guselkumab-for-patients-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying a skin condition called moderate-to-severe plaque psoriasis. This condition causes red, scaly patches on the skin that can be itchy and painful. The study is testing a treatment called Guselkumab, which is given as an injection. Guselkumab is a type of protein that helps to reduce inflammation and improve the appearance of the skin. The study will also use a placebo, which looks like the treatment but does not contain any active medicine.

The purpose of the study is to find out if people who respond very well to Guselkumab can maintain control of their psoriasis with less frequent doses. Participants will receive injections of Guselkumab every 16 weeks over a period of time. The study will monitor how well the treatment works in keeping the skin clear and how long the effects last. Participants will be randomly assigned to different groups, and neither the participants nor the researchers will know who is receiving the actual treatment or the placebo.

The study will last until week 68, and participants will have regular check-ups to assess their skin condition. The main goal is to see how many people achieve a significant improvement in their psoriasis by the end of the study. This research aims to provide more information on how to effectively manage moderate-to-severe plaque psoriasis with Guselkumab.

]]> Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More https://clinicaltrials.eu/trial/study-on-adjustable-brodalumab-dosage-for-patients-with-moderate-to-severe-plaque-psoriasis-weighing-120-kg-or-more/ Wed, 29 Apr 2026 14:28:45 +0000 https://clinicaltrials.eu/trial/study-on-adjustable-brodalumab-dosage-for-patients-with-moderate-to-severe-plaque-psoriasis-weighing-120-kg-or-more/ This clinical trial is focused on studying the effects of a medication called brodalumab in individuals with moderate-to-severe plaque psoriasis, a skin condition that causes red, scaly patches. The study is specifically for those who weigh 120 kg or more. Brodalumab is administered as a solution for injection using a pre-filled syringe. The trial will compare two different dosing regimens of brodalumab: an adjustable dose and a standard dose. There is also a placebo group involved in the study.

The purpose of the study is to evaluate how well the adjustable dosing regimen of brodalumab works compared to the standard dosing regimen in reducing the symptoms of psoriasis. Participants will receive treatment over a period of 52 weeks. Throughout the study, the effectiveness of the treatment will be assessed by observing changes in the severity and extent of psoriasis symptoms.

Participants will be monitored regularly to track their progress and any changes in their condition. The study aims to determine if the adjustable dosing regimen can provide better control of psoriasis symptoms compared to the standard dosing regimen. This information could help improve treatment options for individuals with moderate-to-severe plaque psoriasis.

]]> Study on Tildrakizumab and Etanercept for Children Aged 6 to 17 with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-tildrakizumab-and-etanercept-for-children-aged-6-to-17-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 14:28:24 +0000 https://clinicaltrials.eu/trial/study-on-tildrakizumab-and-etanercept-for-children-aged-6-to-17-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effects of a medication called tildrakizumab in children aged 6 to under 18 years who have moderate to severe chronic plaque psoriasis. Chronic plaque psoriasis is a skin condition that causes red, scaly patches on the skin. The study aims to understand how well tildrakizumab works and how safe it is for children with this condition. Tildrakizumab is given as a solution for injection under the skin. Another medication, etanercept, and a placebo are also part of the study for comparison purposes.

The study is divided into two parts. In the first part, researchers will determine the best dose of tildrakizumab for children by observing its effects over a 16-week period. In the second part, the study will compare the effectiveness of tildrakizumab to a placebo by measuring improvements in the skin condition of the participants. The goal is to see if there is at least a 75% improvement in the Psoriasis Area & Severity Index (PASI 75 response) and a significant reduction in the Physician’s Global Assessment (PGA) score by the end of the 16 weeks.

Participants will receive injections and be monitored throughout the study to assess the medication’s impact on their psoriasis. The study will help determine if tildrakizumab is a suitable treatment option for children with moderate to severe chronic plaque psoriasis. The trial is expected to continue until 2025, providing valuable information on the safety and effectiveness of this treatment in the pediatric population.

]]> Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy https://clinicaltrials.eu/trial/study-comparing-risankizumab-and-deucravacitinib-for-adults-with-moderate-plaque-psoriasis-eligible-for-systemic-therapy/ Wed, 29 Apr 2026 14:27:45 +0000 https://clinicaltrials.eu/trial/study-comparing-risankizumab-and-deucravacitinib-for-adults-with-moderate-plaque-psoriasis-eligible-for-systemic-therapy/ This clinical trial is focused on studying the effectiveness of two treatments for plaque psoriasis, a skin condition that causes red, scaly patches on the skin. The treatments being compared are risankizumab, known by the code name ABBV-066, and deucravacitinib. Risankizumab is administered as a solution for injection, while deucravacitinib is taken as a film-coated tablet. The purpose of the study is to determine which treatment is more effective for adults with moderate plaque psoriasis who are candidates for systemic therapy, which means they need treatment that affects the entire body.

The study will be conducted over a period of 52 weeks. Participants will be randomly assigned to receive either risankizumab or deucravacitinib. During the first 16 weeks, the effectiveness of each treatment will be assessed. If a participant does not achieve a significant improvement with deucravacitinib, they may switch to risankizumab for the remainder of the study. The main goal is to see if risankizumab can achieve a greater reduction in psoriasis symptoms compared to deucravacitinib.

Throughout the study, participants will be monitored to evaluate the reduction in psoriasis symptoms, using measures such as the Psoriasis Area and Severity Index (PASI) and the static Physician’s Global Assessment (sPGA). These assessments help determine the extent of improvement in the skin condition. The study aims to provide valuable information on the best treatment options for individuals with moderate plaque psoriasis.

]]> Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis https://clinicaltrials.eu/trial/study-on-bimekizumab-and-ustekinumab-for-children-and-teens-with-moderate-to-severe-plaque-psoriasis/ Wed, 29 Apr 2026 14:27:17 +0000 https://clinicaltrials.eu/trial/study-on-bimekizumab-and-ustekinumab-for-children-and-teens-with-moderate-to-severe-plaque-psoriasis/ This clinical trial is focused on studying the effects of two treatments for moderate to severe plaque psoriasis in children and teenagers aged 6 to less than 18 years. Plaque psoriasis is a skin condition that causes red, scaly patches on the skin. The study will compare the effectiveness and safety of two medications: bimekizumab and ustekinumab. Bimekizumab, also known by its code name UCB4940, and ustekinumab are both given as a solution for injection under the skin.

The purpose of the study is to evaluate how well bimekizumab works compared to ustekinumab in treating children and adolescents with this condition. Participants will receive either bimekizumab, ustekinumab, or a placebo, which is a substance with no active medication. The study will last for a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their progress and any side effects.

Throughout the study, doctors will assess the improvement in the skin condition using specific measures, such as the Psoriasis Area and Severity Index (PASI) and the Investigator’s Global Assessment (IGA). These assessments will help determine the effectiveness of the treatments. The study will also monitor any changes in the participants’ overall health, including growth and quality of life, to ensure the safety of the treatments being tested.

]]> Study on the Effectiveness and Safety of JNJ-77242113 for Treating Plaque Psoriasis in Special Areas for Patients with Moderate to Severe Symptoms https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-jnj-77242113-for-treating-plaque-psoriasis-in-special-areas-for-patients-with-moderate-to-severe-symptoms/ Wed, 29 Apr 2026 14:25:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-jnj-77242113-for-treating-plaque-psoriasis-in-special-areas-for-patients-with-moderate-to-severe-symptoms/ This clinical trial is focused on studying the effectiveness and safety of a new treatment for plaque psoriasis, a skin condition that causes red, scaly patches. The treatment being tested is a medication known as JNJ-77242113, which is taken as a film-coated tablet. The study will compare the effects of this medication to a placebo, which looks like the real medication but does not contain the active ingredient.

The purpose of the study is to evaluate how well JNJ-77242113 works in people with moderate to severe plaque psoriasis, especially in areas that are difficult to treat. Participants will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. The study will last for several months, during which participants will take the medication or placebo and attend regular check-ups to monitor their progress and any side effects.

Throughout the study, the main goal is to see if the medication can improve the condition of the skin by reducing the severity of the psoriasis patches. Participants will be assessed at various points to determine if there is a noticeable improvement in their skin condition. This trial aims to provide valuable information about the potential benefits of JNJ-77242113 for individuals living with plaque psoriasis.

]]>